-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

3520 Failure and out of Specification Manufacturing of Autologous CAR-T Cells Could be Associated with a High Concentration of Total Nucleated Cells, CD3+ Cells and Neutrophils in the Apheresis ProductClinically Relevant Abstract

Program: Oral and Poster Abstracts
Session: 711. Cell Collection and Processing: Poster II
Hematology Disease Topics & Pathways:
Research, Biological therapies, Translational Research, assays, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Therapies, Technology and Procedures
Sunday, December 10, 2023, 6:00 PM-8:00 PM

Guillaume Cohet, PharmD1*, Cedrik NGO-Chin2*, Nadia Douki2*, Marion Desniaux2*, Stellie Cornu2*, Justine Nasone, PharmD2*, Audrey Cras, PharmD, PhD3*, Lionel Faivre, PharmD, PhD2*, Nathalie Parquet, MD4*, Anne Brignier, MD4*, Dehbia Menouche, MD5*, Emmanuelle Lesprit, MD6*, Nabih Azar, MD7*, Ramdane Belhocine, MD8*, Isabelle Madelaine, PharmD1*, Romain de JORNA, PharmD9*, Jerome Larghero, PharmD, PhD2* and Miryam Mebarki10*

1Pharmacy department, Saint-Louis Hospital, APHP, Paris, France
2Cell Therapy Unit, Saint-Louis Hospital, APHP, Paris, France
3Cell Therapy Unit, Saint Louis Hospital, APHP, Paris, France
4Apheresis, Saint-Louis Hospital, APHP, Paris, France
5Apheresis, Hopital Henri Mondor, Créteil, France
6Robert Debré Hospital, EFS, Paris, France
7Apheresis, La Pitié Salpétrière Hospital, APHP, Sorbonne Universite, Paris, France
8Apheresis, Saint Antoine Hospital, Paris, FRA
9Pharmacy department, Saint-Louis Hospital, APHP, Paris, FRA
10Cell Therapy Unit, Saint-Louis Hospital, APHP, University Paris Cité, Paris, France

Manufacturing capacities of commercial autologous chimeric antigen receptor (CAR)-T cells have been significantly increased during the last years, allowing treatment of a larger patient cohort. However, this was associated with the emergence of several failures and out of specifications (OOS), resulting in treatment delay. The aim of our study was to identify early indicators related to apheresis products that can predict CAR-T cells manufacturing failure or OOS. To this end, we analyzed manipulation processes of cellular starting materials (conservation, freezing, cryopreservation) and quality controls (QC) including count and/or concentration of total nucleated cells (TNC), CD3+, CD4+, CD8+ cells, platelets, monocytes and neutrophils.

We analyzed 802 apheresis products that were collected for the manufacturing of axicabtagene ciloleucel (axi-cel, n=303), tisagenlecleucel (tisa-cel, n=403), brexucatagene autoleucel (brexu-cel, n=44) and idecabtagene vicleucel (ide-cel, n=52). This cohort was classified into 3 groups: failure (CAR-T cells not produced), OOS (CAR-T cells produced but non-compliant) and compliant.

We identified 21 failures and 24 OOS, resulting in either no treatment or a significant delay when the OOS were injected (57.6±17.5d versus 45.9±16.3d in compliant group, p=0.0405). Among each CAR-T cells product, 13 (4.3%) axi-cel, 30 (7.4%) tisa-cel, 1 (2.3%) brexu-cel and 1 (1.9%) ide-cel were concerned. The main causes of failures were low viability (33.3%), non-compliant dose (28.6%), microbiological contamination (23.8%) and formulation concerns (14.3%). In OOS, low viability (41.7%), low dose (29.2%), microbiological contamination (4.2%), formulation (12.5%) and safety concerns (8.3%; i.e high vector copy number) were identified. 17 products (13 failures and 4 OOS) were successfully remanufactured without an increased delay comparing to compliant products (47.5±15.9 and 47.3±15.1 respectively versus 45.9±16.3 d).

To identify risk factors of manufacturing failure or OOS due to non-compliant viability and/or dose, we analyzed processing and QC of collected cellular starting materials. OOS were associated with a high concentration of TNC (146.7±94.3 vs 61.6±36.1 x106/mL, p=0.009) and CD3+ cells (88.6±76.5 vs 26.0±21.9 x106/mL, p=0.0112) in cell collections, while failures were observed in apheresis with high neutrophils concentration (14.3±15.03 x103/µL vs 6.0±7.6 x103/µL, p=0.0195). Interestingly, neutrophils were significantly decreased in apheresis collected for CAR-T cells remanufacturing which succeed (p=0.0156).

This preliminary study showed that high TNC, CD3+ cells and neutrophils concentration in the apheresis product might be predictive factors of failures and/or OOS of commercial autologous CAR-T cells manufacturing.

Disclosures: Cohet: Kite/Gilead: Consultancy. Parquet: Kite/Gilead: Honoraria; Sanofi: Honoraria; Novartis: Honoraria. Brignier: Kite/Gilead: Honoraria. Menouche: Vertex: Consultancy; Sandoz: Consultancy; Sanofi: Honoraria. Azar: Janssen: Consultancy; Sanofi: Consultancy, Honoraria. Belhocine: Sanofi: Honoraria. Madelaine: Novartis: Consultancy; Kite/Gilead: Consultancy. de JORNA: Kite/Gilead: Honoraria; BMS: Consultancy; Novartis: Honoraria. Larghero: BMS: Consultancy; Janssen: Consultancy; Novartis: Consultancy; Kite/Gilead: Consultancy. Mebarki: BMS: Consultancy; Janssen: Consultancy; Novartis: Consultancy; Kite/Gilead: Consultancy, Honoraria.

Previous Abstract | Next Abstract >>
*signifies non-member of ASH